Developing Nations and the Compulsory License: Maximizing Access to Essential Medicines While Minimizing Investment Side Effects
David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Jack Alan Reynolds
Learn more about PhilPapers
Journal of Law, Medicine and Ethics 37 (2):209-221 (2009)
This manuscript addresses how developing countries can maximize access to essential medicines and minimize unwanted side-effects within the legal environment of a compulsory license regime. While compulsory licensing can play a role in improving public health, external social and political conditions must be considered in order to make licensing an effective practice
|Keywords||No keywords specified (fix it)|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
No references found.
Citations of this work BETA
Jorn Sonderholm (2010). Ethical Issues Surrounding Intellectual Property Rights. Philosophy Compass 5 (12):1107-1115.
Jerome H. Reichman (2009). Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options. Journal of Law, Medicine and Ethics 37 (2):247-263.
Kevin Outterson (2009). INTRODUCTION: Pharmaceutical Innovation: Law & the Public's Health. Journal of Law, Medicine and Ethics 37 (2):173-175.
Similar books and articles
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Access to Essential Medicines (B). Journal of Business Ethics Education 2 (1):123-132.
N. Craig Smith & Anne Duncan (2005). GlaxoSmithKline and Developing Country Access to Essential Medicines (A). Journal of Business Ethics Education 2 (1):97-121.
Nicole Hassoun (2012). Global Health Impact: A Basis for Labeling and Licensing Campaigns? Developing World Bioethics 12 (3):121-134.
Richard E. Ashcroft (2005). Access to Essential Medicines: A Hobbesian Social Contract Approach. Developing World Bioethics 5 (2):121–141.
Klaus M. Leisinger (2009). Corporate Responsibilities for Access to Medicines. Journal of Business Ethics 85 (1):3 - 23.
Udo Schüklenk & Richard E. Ashcroft (2002). Affordable Access to Essential Medication in Developing Countries: Conflicts Between Ethical and Economic Imperatives. Journal of Medicine and Philosophy 27 (2):179 – 195.
Devi Sridhar (2008). Improving Access to Essential Medicines: How Health Concerns Can Be Prioritised in the Global Governance System. Public Health Ethics 1 (2):83-88.
Anand Grover, Brian Citro, Mihir Mankad & Fiona Lander (2012). Pharmaceutical Companies and Global Lack of Access to Medicines: Strengthening Accountability Under the Right to Health. Journal of Law, Medicine and Ethics 40 (2):234-250.
Debora Diniz (2009). Rationing the Access to High Cost Medicines in Developing Countries. Developing World Bioethics 9 (2).
Michael Ravvin (2008). Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions. Public Health Ethics 1 (2):110-123.
Wolfgang Kerber & Claudia Schmidt, Microsoft, Refusal to License Intellectual Property Rights, and the Incentives Balance Test of the EU Commission.
Joo-Young Lee & Paul Hunt (2012). Human Rights Responsibilities of Pharmaceutical Companies in Relation to Access to Medicines. Journal of Law, Medicine and Ethics 40 (2):220-233.
Matthew Rimmer (2008). Race Against Time: The Export of Essential Medicines to Rwanda. Public Health Ethics 1 (2):89-103.
Rudolf V. van Puymbroeck (2010). Basic Survival Needs and Access to Medicines – Coming to Grips with TRIPS: Conversion + Calculation. Journal of Law, Medicine and Ethics 38 (3):520-549.
Added to index2010-09-13
Total downloads16 ( #116,465 of 1,410,123 )
Recent downloads (6 months)2 ( #107,970 of 1,410,123 )
How can I increase my downloads?